Abionic

Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.

Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.

Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.

Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.

Abionic appreciates the support it has received from:

Abionic headquartered in Switzerland, Europe, operates in the Biotechnology, Life Science, Health Care, Pharmaceutical, Medical, Nanotechnology sector. The company focuses on Biotechnology and has secured $6.0B in funding across 216 round(s). With a team of 51-100 employees, Abionic is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Abionic, raised $4.0M. Discover more about their projects, partnerships, and impact on our platform.